TRYWALK-FORTE Tablets

 For Better Healing in Traumatic Condition

COMPOSITION – Trypsin BP 48mg + Bromelain 90mg+ Rutoside tihydrate 100mg

Category:

Description

The proteolytic enzymes, trypsin and bromelain, Is a synergistic combination that exhibits anti-inflammatory, anti-edematous and antioxidant properties. The combination help in mitigating excessive inflammatory reactions and resulting impairment of the natural defense mechanism. 

TRYPSIN (Proteolytic enzymes)

  • A proteolytic enzyme that modulates the inflammatory response useful in rheumatologic diseases.
  • Trypsin  circulates  in  blood  stream  bound  to  alpha-1 antitrypsin  (α1-AT)  and  has  more  affinity  to  it  than plasmin, allowing more plasmin  to  be  available  for fibrinolysis.

(Note: Around 10% of an orally  administered trypsin dose ends up in the blood.)

  • Helps in the management of burns – enhanced fibrinolysis, enhanced wound-healing and lowering of proinflammatory cytokines.
  • BROMELAIN (Proteolytic enzymes /protein-digesting enzymes)
  • Obtained from the pineapple plant has fibrinolytic, antithrombotic, and anti-inflammatory properties, which help in controlling the complications of burns.
  • Stimulates the conversion of plasminogen to plasmin, resulting in increased fibrinolysis. Improves total symptom score, stiffness and physical function in osteoarthritis patients.

       

  • Its fibrinolytic action aids in the reabsorption of edema into the blood circulation. Proven successful oral enzyme therapy for oral surgery patients.
  • RUTOSIDE TRIHYDRATE (Flavonoid-3-o-glycosides)
  • Rutoside aka vitamin P is a polyphenolic  bioflavonoid,  extracted  from natural  sources such  as  oranges, lemons,  grapes,  limes, berries,  and  peaches.
  • Possesses pharmacological activities like antioxidant, cytoprotective, vasoprotective, anticarcinogenic, neuroprotective and cardioprotective activities.
  • Inhibits the transcription of proinflammatory factors, TNF-α,  IL-1,  IL-8, & TNF-α, macrophage migration inhibitory  factor (MIF), and chemotactic factors in activated macrophages.

COMBINATION

  • This combination is suggested to have analgesic, anti-inflammatory, anti-edematous and antioxidant properties.
  • The combination therapy is involved in,
  • Favourable modulation of inflammatory mediators, 
  • Enhancement of plasmin levels, 
  • Reduced leukocyte migration to injury site and, 
  • Suppression of the formation of reactive oxygen species.
  • This combination therapy is a promising new treatment modality to reduce pain in Temporomandibular Joint Osteoarthritis because of anti-inflammatory and anti-oxidant effects.